Publications by authors named "Takuya Sho"

Claim this Profile
T
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Masatsugu Ohara, Goki Suda, Risako Kohya, Yutaka Yasui, Kaoru Tsuchiya, Takuya Sho

Hepatol Int· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble Cluster of Differentiation 14 as a Prognostic Marker in Decompensated Cirrhosis With Water Retention.
Masato Nakai, Masatsugu Ohara, Daisuke Yokoyama, Shoichi Kitano, Takatsugu Tanaka, Takuya Sho

Hepatol Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study.
Federica Lo Prinzi, Federico Rossari, Antonio De Rosa, Caterina Vivaldi, Masatoshi Kudo, Takuya Sho

Hepatol Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.
Goki Suda, Masaru Baba, Yoshiya Yamamoto, Sonoe Yoshida, Tetsuhito Muranaka, Takuya Sho

Sci Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cirrhotic Cardiomyopathy: Prevalence and Clinical Impact on Liver Cirrhosis Outcomes.
Takashi Kitagataya, Goki Suda, Takatsugu Tanaka, Shoichi Kitano, Naohiro Yasuura, Takuya Sho

Hepatol Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study.
Goki Suda, Masaya Sugiyama, Hayato Hikita, Akira Nishio, Tomohide Tatsumi, Takuya Sho

Biomark Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study.
Alessandro Vitale, Jung Sun Kim, Giuseppe Cabibbo, Andrea Casadei-Gardini, Massimo Iavarone, Takuya Sho

Liver Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.
Mara Persano, Andrea Casadei-Gardini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Takuya Sho

Oncology· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.
Risako Kohya, Goki Suda, Masatsugu Ohara, Shunichi Hosoda, Takuya Sho

JHEP Rep· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.
Hisatoshi Hanamatsu, Goki Suda, Masatsugu Ohara, Koji Ogawa, Nobuharu Tamaki, Takuya Sho

J Gastroenterol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study.
Zijian Yang, Goki Suda, Takuya Sho, Osamu Maehara, Masatsugu Ohara

Hepatol Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC.
Naohiro Yasuura, Goki Suda, Masatsugu Ohara, Akimitsu Meno, Takuya Sho

Aliment Pharmacol Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Takuya Sho

Liver Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
Takuya Sho, Goki Suda, Masatsugu Ohara, Risako Kohya, Takashi Sasaki

Target Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Takuya Sho

Target Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Margherita Rimini, Bernardo Stefanini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Takuya Sho

Liver Int· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib.
Massimo Iavarone, Eleonora Alimenti, Toshifumi Tada, Shigeo Shimose, Goki Suda, Takuya Sho

Liver Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Takuya Sho

Int J Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
Silvia Camera, Margherita Rimini, Federico Rossari, Toshifumi Tada, Goki Suda, Takuya Sho

Target Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.
Takashi Sasaki, Goki Suda, Masatsugu Ohara, Shunichi Hosoda, Naoki Kawagishi, Takuya Sho, Sho Komukai

Hepatol Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma.
Masatsugu Ohara, Goki Suda, Risako Kohya, Takashi Sasaki, Tomoka Yoda, Takuya Sho

Front Nutr· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Takuya Sho

Eur J Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis.
Masato Nakai, Kenichi Morikawa, Takashi Sasaki, Risako Kohya, Sonoe Yoshida, Takuya Sho

J Gastroenterol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
Shunichi Hosoda, Goki Suda, Takuya Sho, Koji Ogawa, Megumi Kimura

Liver Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.
Risako Kohya, Goki Suda, Masatsugu Ohara, Takashi Sasaki, Tomoka Yoda, Takuya Sho

Cancers (Basel)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis